RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2
{{output}}
Background: Since the emergence of SARS-CoV-2, the causative agent of COVID-19, the global health landscape has confronted an unprecedented and formidable challenge. The SARS-CoV-2 receptor-binding domain (RBD) is a key antigen i... ...
